ArticleChemistry & biodiversity2026
Biochemical Characterization of a Kunitz-Type Protease Inhibitor From Mimosa regnellii and Its Effects on Melanoma Cell Viability and Angiogenesis.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Cancer is a term used to represent more than 100 diseases, including malignant tumors of different localizations. Among these types, cutaneous melanoma is one of the most common types of skin cancer worldwide. Newer, non-invasive, and more effective forms of treatment are urgently needed. Recently, the cancer membrane has emerged as a novel target for new anticancer drugs. Serine protease inhibitors are researched across all kingdoms; however, the Plantae kingdom is a more sustainable producer of bioactive molecules, including serine protease inhibitors. In this study, a Kunitz trypsin inhibitor (JTI) purified by RP-HPLC from Mimosa regnellii seeds was sequenced, its inhibitory activity quantified, and its inhibition constant determined. It was then tested for its ability to induce cell death via the apoptotic pathway in B16-F10 mouse melanoma cells. To evaluate its pro-apoptotic capacity, the inhibitor's effects on reactive oxygen species release, calcium release, cell morphological changes, and the inhibition of angiogenic and migratory activities of rabbit endothelial cells (RaEC) were also assessed in vitro. Tests for toxicity against normal cells were performed, confirming that JTI acts on melanoma cells with an IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.